首页> 外文期刊>Endocrine journal >Clinical prognostic index for recurrence of papillary thyroid carcinoma including intraoperative findings
【24h】

Clinical prognostic index for recurrence of papillary thyroid carcinoma including intraoperative findings

机译:甲状腺乳头状癌复发的临床预后指标,包括术中发现

获取原文
       

摘要

References(37) Cited-By(7) This study created a new staging system using a risk model that employed clinical factors that were associated with recurrence, verified by preoperative clinical information and intraoperative finding and was compared with other staging systems. A review was conducted of patients who have undergone thyroidectomy and followed-up between January 1, 1983 and September 31, 2007 at Yonsei University Wonju Christian Hospital. The final prognostic staging system was defined as University of Yonsei clinical staging system (Prognostic score = 0.03 × Age + 0.8 × (if male gender) + 0.5 × (if extrathyroidal tumor extension present) + 0.7 × (if clinically apparent lymph node metastasis present), Stage I, less than 1.50; Stage II, 1.50 to 2.29; Stage III, 2.30 to 3.29; Stage IV 4, 3.3 or more). Compared with the other staging systems, the proportion of variation explained (PVE %) was calculated for each. The University of Yonsei clinical staging system appeared to be first as an accurate prognosis predictor with 11.9%. New staging system can predict recurrence and has advantage can use preoperative clinical information and intraoperative finding. Those who are diagnosed as high risk patients using the new staging system should be treated with aggressive surgical treatment and close follow-up.
机译:参考文献(37)Cited-By(7)该研究使用风险模型创建了一个新的分期系统,该模型采用了与复发相关的临床因素,并通过术前临床信息和术中发现进行了验证,并与其他分期系统进行了比较。在延世大学原州基督教医院对1983年1月1日至2007年9月31日期间接受甲状腺切除术和随访的患者进行了回顾。最终的预后分期系统定义为延世大学临床分期系统(预后评分= 0.03×年龄+ 0.8×(如果是男性)+ 0.5×(如果存在甲状腺外肿瘤扩展)+ 0.7×(如果存在临床上明显的淋巴结转移) ),第一阶段,低于1.50;第二阶段,1.50至2.29;第三阶段,2.30至3.29;第四阶段4,3.3或更高)。与其他分期系统相比,针对每个分期系统计算了所解释的差异比例(PVE%)。延世大学的临床分期系统似乎以11.9%的准确率成为第一个准确的预后预测指标。新的分期系统可以预测复发,并且具有可以利用术前临床信息和术中发现的优势。使用新的分期系统被诊断为高危患者的患者应接受积极的外科治疗和密切随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号